dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Harrington, Kevin |
dc.contributor.author | Burtness, Barbara |
dc.contributor.author | Greil, Richard |
dc.contributor.author | Soulières, Denis |
dc.contributor.author | Tahara, Makoto |
dc.contributor.author | de Castro Junior, Gilberto |
dc.contributor.author | Braña Garcia, Irene |
dc.contributor.author | Basté Rotllan, Neus |
dc.date.accessioned | 2023-03-03T08:11:55Z |
dc.date.available | 2023-03-03T08:11:55Z |
dc.date.issued | 2023-02-01 |
dc.identifier.citation | Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2023 Feb 1;41(4):790–802. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/9099 |
dc.description | Pembrolizumab; Carcinoma de cèl·lules escamoses de cap i coll |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;41(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Cap - Càncer - Tractament |
dc.subject | Coll - Càncer - Tractament |
dc.subject | Anticossos monoclonals - Ús terapèutic |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Head and Neck Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antibodies, Monoclonal |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.21.02508 |
dc.subject.decs | neoplasias de cabeza y cuello |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | anticuerpos monoclonales |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1200/JCO.21.02508 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Harrington KJ] The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, United Kingdom. [Burtness B] Yale Cancer Center and Yale School of Medicine, New Haven, CT. [Greil R] Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria. Paracelsus Medical University Hospital, and Cancer Cluster Salzburg, Salzburg, Austria. [Soulières D] Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada. [Tahara M] National Cancer Center Hospital East, Kashiwa, Japan. [de Castro G Jr] Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil. [Brana I, Basté N] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 36219809 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |